Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)

Subcutaneous allergen immunotherapy (SCIT) with aeroallergens is covered for patients with allergic rhinitis/conjunctivitis, allergic asthma, combined disease, and dust-mite–related atopic dermatitis when a clinically relevant allergic component is documented (symptoms on natural exposure and specific IgE). Coverage requires prior optimization of environmental control and pharmacotherapy (or documented reasons for failure/intolerance), objective IgE testing or equivalent confirmation, and adherence to provider and facility supervision requirements; an initial course is generally 3–5 years with evaluation every 6–12 months and cessation of reimbursement if no benefit by two years.

"SCIT using aeroallergen preparations is covered for allergic rhinitis and/or allergic conjunctivitis (seasonal, perennial, or both)."

Sign up to see full coverage criteria, indications, and limitations.